Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes

A compound of formula I

• wherein:
• Ring A is cyclohexane-1,3-diyl;
• R1 and, R2 are independently selected from the group consisting of H, (C1-C6)-alkyl, and O—(C1-C6)-alkyl;
• R3 is selected from the group consisting of H, and (C1-C6)-alkyl;
• W is CH;
• o is 1;
• X is —CH2—O—CH2—;
• Y is selected from the group consisting of CO;
• n is 1;
• R4 is selected from the group consisting of H, F, and (C1-C6)-alkyl;
• R5 is selected from the group consisting of H, F, and (C1-C6)-alkyl;
• R6 is selected from the group consisting of H, F, and (C1-C6)-alkyl;
• or
• R5 and R6 together with the carbon atoms to which they are attached form (C3-C6) -cycloalkane-1,2-diyl;
• R7 is selected from the group consisting of
• H, F,
• (C1-C6)-alkyl, (C6-C10)-aryl, and
• NR10R11;
• R8 is H or (C1-C6)-alkyl;
• R10 is C(O)—O—(C1-C6)-alkyl-(C6-C10)-aryl;
• and
• R11 is H or (C1-C6)-alkyl;
• or a salt thereof.